A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg TID in the Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome
Latest Information Update: 31 Jan 2023
Price :
$35 *
At a glance
- Drugs Rifaximin (Primary)
- Indications Irritable bowel syndrome
- Focus Registrational; Therapeutic Use
- Acronyms TARGET-1
- Sponsors Bausch Health Companies; Salix Pharmaceuticals
- 23 May 2021 Results (n=3837) of pooled post hoc analysis of assessing efficacy of 3 Phase III studies TARGET-1, TARGET-2 and TARGET-3, presented at the Digestive Disease Week 2021.
- 23 May 2021 Results (n=1258) of post-hoc pooled analysis from two phase 3 studies assessing efficacy of rifaximin in improving both abdominal pain and bloating in patients with IBS-D presented at the Digestive Disease Week 2021
- 17 May 2021 According to a Salix Pharma media release, results of pooled post hoc analysis will be presented at Digestive Disease Week (DDW) 2021.